Home | Welcome to Contract Pharma   
Last Updated Saturday, January 31 2015

Print

Topics - Preclinical Outsourcing


Refine by Date:
From: To:
Using Technology to Improve Study Startup
By Roshan Padbidri and Maria Breaux , goBalto Singapore and goBalto San Francisco
Published January 29, 2015
A necessary step that provides companies with a competitive advantage. Read More »
Jump Starting the Non-Profit Research Engine
By Kate Hilyard , Managing Director, BioFocus
Published January 29, 2015
How CROs are teaming up with disease foundations to accelerate drug discovery. Read More »
What is Driving the Outsourcing Market?
By Divyaa Ravishankar, Senior Industry Analyst, Frost & Sullivan Life Sciences
Published January 29, 2015
CRO industry generates healthy partnerships through co-development of drugs, diagnostics and demand for functional services. Read More »
Newsmakers: James Foster
By Kristin Brooks, Contract Pharma
Published May 1, 2014
Charles River Labs’ CEO James Foster is looking upstream to offer clients a faster “go/no go” indicator for preclinical work Read More »
By Gil Roth
Published November 13, 2013
Discovery Labs, Fibrogen, Pluristem, RXi, Tekmira, Vivus, Zysis Read More »
By Gil Roth
Published November 13, 2013
Strong benefits in non-human primate studies Read More »
The Wild West of Basic Discovery
By Nancy Gillett, Charles River Laboratories
Published November 13, 2013
R&D outsourcing issues Read More »
By Kristin Brooks
Published November 6, 2013
Q&A with Ubavka DeNoble, M.D. about small and mid-size company needs Read More »
By Gil Roth
Published November 5, 2013
Triggers $15 mil. payment from Bayer Read More »
By Gil Roth
Published November 5, 2013
OMS721 cuts blood vessel development in half Read More »
By Gil Roth
Published November 1, 2013
Regen BioPharma signs clinical supply contract Read More »
Newsmakers: Biomarkers
By Gil Y. Roth, Contract Pharma
Published October 9, 2013
Vellalore Kakkanaiah of PPD on biomarker development Read More »
By Gil Roth
Published September 30, 2013
Phase I/II trial in type 2 reaches primary endpoints Read More »
By Gil Roth
Published September 26, 2013
Dompe, Exelixis, Lilly, Lumena, NovaRx, ProMetic, Sarepta, Read More »
By Gil Roth
Published September 26, 2013
PBI-4050 passes fox testing, safe to advance Read More »


Receive free Contract Pharma Direct emails
Sign up now to receive the weekly newsletter, and more!

Enter your email address:
Follow Contract Pharma On